Brain penetration of ketamine: Intranasal delivery VS parenteral routes of administraion

Journal of Psychiatric Research
Vivian NaidooSooraj Baijnath

Abstract

Ketamine is approved by the FDA to be used as an anesthetic however, recent reports have exhibited its success in the treatment of major depressive disorder (MDD). Studies have suggested that a sub-anesthetic dose produces rapid antidepressant activity providing significant symptomatic relief particularly in patients with a history of treatment resistant depression (TRD). Many reports have been published on the intranasal (IN) efficacy of ketamine in the treatment of depression, however studies that have investigated the effects of the route of administration on drug delivery to the brain appear to be absent in literature. Therefore, in this study, a single dose (15 mg/kg body weight) was administered via different routes of administration [oral (PO), intranasal (IN) and intraperitoneal (IP)] to healthy male Sprague-Dawley rats in order to determine the brain tissue pharmacokinetics of ketamine. A novel validated liquid chromatography-mass spectrometry (LC-MS) method was developed using a fused core column for the determination of ketamine in plasma and brain homogenates. While IP administration resulted in favorable concentrations in the brain and plasma; IN administration, which is supposed to favour drug delivery to the brai...Continue Reading

References

May 1, 1982·Journal of Pharmaceutical Sciences·J A ClementsI S Grant
Jun 19, 2003·JAMA : the Journal of the American Medical Association·Ronald C KesslerUNKNOWN National Comorbidity Survey Replication
Jul 31, 2003·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Maria Esther Rodriguez RosasIrving W Wainer
Dec 30, 2011·Clinical Pharmacology and Therapeutics·J W Murrough
Jun 19, 2012·Biological Psychiatry·Marije Aan Het RotSanjay J Mathew
Feb 26, 2013·British Journal of Clinical Pharmacology·Marieke NiestersAlbert Dahan
Apr 23, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michel Hamon, Pierre Blier
Dec 11, 2013·European Psychiatry : the Journal of the Association of European Psychiatrists·W ZhouJ-J Yang
Jan 11, 2014·Frontiers in Pharmacology·Caroline A Browne, Irwin Lucki
Feb 18, 2014·Current Neuropharmacology·H W W Hasselmann
May 14, 2014·Biological Psychiatry·Kyle A B LapidusJames W Murrough
Mar 31, 2016·Clinical Pharmacokinetics·Marko A PeltoniemiTeijo I Saari
Apr 8, 2016·Evidence-based Mental Health·Jaclyn SchwartzDan V Iosifescu
Mar 11, 2017·Journal of Pharmaceutical and Biomedical Analysis·Mahmoud HasanStefan Oswald
Aug 2, 2017·The Lancet. Psychiatry·Brooke ShortColleen K Loo

❮ Previous
Next ❯

Citations

May 22, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Robert K HofstetterAndreas Link
Dec 5, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Heidi N du PreezJohnson Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.